FDA has downgraded its expectations for usage of its 483 dispute resolution procedure
This article was originally published in The Gold Sheet
Executive SummaryAt the request of industry, the agency issued draft guidance in September 2003 outlining a two-tiered formal process for resolving scientific and technical disputes that arise during inspections. The agency later estimated that every year, 25 companies would file a Tier One request and five would appeal to Tier Two. Based on the final guidance, published Jan. 12, 2006, FDA estimated in a Jan. 22, 2008, Federal Register notice that there would be only two Tier One requests and one Tier Two appeal in any given year
You may also be interested in...
Rutgers University professor testifies in support of bill directing the FDA to designate National Centers of Excellence in Continuous Manufacturing; other bills target generic labeling, orphan exclusivity and counterfeit devices.
Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.
Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.